Mayer K, Hein-Rothweiler R, Schüpke S, et al. - This phase 2 randomized clinical trial was conducted with patients experiencing stable ischemic heart disease receiving elective percutaneous coronary intervention (PCI), to investigate whether revacept (a novel, lesion-directed antithrombotic drug, acting as a competitive antagonist to platelet glycoprotein VI) has efficacy and safety in this patient population. Patients included in this trial were administered a single intravenous infusion of revacept, 160 mg, revacept, 80 mg, or placebo before the initiation of PCI on top of standard antithrombotic therapy. According to findings, no reduction in myocardial injury was conferred by revacept. Few bleeding events occurred and no significant differences existed between treatment arms. Experts found a small but statistically significant impact of the 160-mg dose of revacept on collagen-induced but not adenosine 5′-diphosphate–induced platelet aggregation.